Role of MicroRNA-29 in Uterine Leiomyoma Pathogenesis

描述（由申请人提供）：平滑肌瘤是高度弥漫性的子宫良性肿瘤，在50岁以下的女性中总患病率为70%。它们是美国子宫切除术的主要原因，占每年60万例子宫切除术的近50%，每年医疗费用为340亿美元。尽管其流行和公共卫生的影响，细胞和分子机制调节平滑肌瘤的发展和生长还没有很好地理解。从表型上看，这些肿瘤与邻近的正常组织不同，主要是由于细胞外基质成分的过度产生，特别是主要的纤维状胶原（I，II和III）。我们和其他人已经证明，除了LEIO和MYO之间的差异表达基因外，还有microRNA的差异表达，这表明它们在这些肿瘤的基因调控中发挥作用。MicroRNA是一类负调控基因表达的非编码小RNA。虽然有几项研究已经记录了激素和生长因子对平滑肌瘤中miRNA的调节，但没有一项研究表明它们在其主要区别病理学发现方面的功能作用：过度胶原沉积。我们的实验室已经发现，与正常子宫肌层组织相比，miR-29家族的所有成员（29 a，29 b，29 c）在平滑肌瘤中下调。基于最近在其他纤维化疾病中的研究和本申请中包括的初步数据，我们假设miRNA-29家族的这种失调在平滑肌瘤中发现的异常细胞外基质组分中起着功能性作用。为了解决这一假设，我们提出了以下两个具体目标：在具体目标1中，我们试图确定TGF-β 3调节子宫平滑肌瘤中miR-29水平的机制。已知TGF-β 3在平滑肌瘤中的浓度高于邻近的正常子宫肌层组织。为了确定其在调节miRNA-29中的作用，我们将进行SMAD 2/3敲低和染色质免疫沉淀研究。在具体目标2中，我们将确定miR-29家族（a/B/c）对子宫平滑肌瘤中过量主要纤维胶原蛋白产生的贡献。miRNA-29的作用将使用敲低和过表达研究来评估。这些研究的结果不仅将提供有关平滑肌瘤中所见的过量细胞外基质的机制信息，而且还将为未来的临床前研究奠定基础，因为我们对人类疾病中的miRNA和基于寡核苷酸的治疗方法的理解将继续扩大。

DESCRIPTION (provided by applicant): Leiomyomas are highly pervasive benign tumors of the uterus that have an overall prevalence of 70% in women by the age of 50. They are the leading cause of hysterectomy in the United States, accounting for almost 50% of the 600,000 hysterectomies performed annually and $34 billion dollars in annual healthcare costs. Despite their prevalence and public health impact, the cellular and molecular mechanisms regulating the development and growth of leiomyoma are not well understood. Phenotypically, these tumors are distinct from the adjacent normal tissue largely due to the overproduction of extracellular matrix component, especially the major fibrillar collagens (I, II, and III). We, and others, have demonstrated that in addition to differentially expressed genes between LEIO and MYO, there is differential expression of microRNAs, suggesting that they play a role in gene regulation of these tumors. MicroRNAs are a class of small non-coding RNAs that negatively regulate gene expression. While several studies have documented hormonal and growth factor regulation of miRNAs in leiomyomata, none have demonstrated a functional role for them in terms of their main distinguishing pathological finding: excessive collagen deposition. Our lab has found that all of the members of the miR-29 family (29a, 29b, 29c) are downregulated in leiomyoma versus normal myometrial tissue. Based on recent studies in other fibrotic diseases and preliminary data included in this application, we hypothesize that this dysregulation of the miRNA-29 family plays a functional role in the aberrant extracellular matrix components found in leiomyomata. To address this hypothesis, we propose the following two specific aims: In Specific Aim 1 we seek to determine the mechanism by which TGF-¿3 regulates miR-29 levels in uterine leiomyomas. TGF-¿3 is known to be present in higher concentrations in leiomyoma versus adjacent normal myometrial tissue. To determine its role in the regulation of miRNA-29, we will perform SMAD2/3 knockdown and chromatin immunoprecipitation studies. In Specific Aim 2, we will determine the contribution of the miR-29 family (a/b/c) to the excess major fibrillar collagen production in uterine leiomyoma. The role of miRNA-29 will be assessed using knockdown and overexpression studies. The results from these studies will not only provide mechanistic information on the excess extracellular matrix seen in leiomyomas, but will also lay the foundation for future preclinical studies as our understanding of both miRNAs in human disease and oligonucleotide based therapeutics continues to expand.